Tau Imaging Agents

Tau Imaging Agents – Target Pipeline List

Target: Tau; neurofibrillary tangles; NFTs; 3R, 4R and 3R/4R types of tau deposits; tau protein aggregates

This Target Pipeline list provides an overview of small molecule imaging agents targeting tau in the brain in development for visualization of tauopathies and tau-targeted treatment effects.

There is great interest in agents to visualize tau pathology in diverse tauopathies, including Mild Cognitive Impairment (MCI), dementia due to Alzheimer’s disease (AD), Corticobasal Degeneration Syndrome (CBS), and Progressive Supranuclear Palsy (PSP). Tau imaging may be helpful to better understand the natural history of tau pathology in rare tauopathies as well as Alzheimer’s Disease, but also may have important value in the development of effective treatments for these diseases.

A number of a novel investigational [18F]-labeled positron emission tomography (PET) imaging tracers are in development and use to support patient selection and efficacy evaluation in clinical trials of novel tau-targeted drug candidates.

A Phase 3 study of the most advanced molecule in the pipeline of Tau imaging agents met its two primary endpoints, defined as predicting brain tau pathology and predicting Alzheimer’s disease diagnosis.

La Merie Publishing offers a low-cost product service providing information about active R&D projects for a given target in the format of Word tables. The Word document with the Table is delivered by e-mail within 24 hours after receipt of the confirmed order. Usually, delivery time is less than one hour if ordered during European business hours.

Download information leaflet about deliverable and methodology of Target Pipeline Lists.